Research and Development Committee. 13.1.3.1 Investigates those areas of science and technology which impact the validity, reliability, and use of the polygraph technique and reports the findings of said investigations to the Board and the General Membership as appropriate.
Research and Development Committee. 5.1. The Parties shall form a Research and Development Committee (the “R & D Committee”), that shall be active for the duration of the Feasibility Program and the Development Plan. During Stage 1 the R & D Committee shall have the charter to adjust and amend the Feasibility Program (per Protein), as required for scientific or technological reasons. During Stage 2 the R & D Committee shall monitor the performance of the Development Plans, the research and other activities being conducted thereunder, and shall issue its recommendations in writing to the Parties, but shall have no decision making authority. The R&D Committee shall be comprised of four (4) members, having one vote each, of which two (2) shall be appointed by each Party, including one co-chairperson appointed by each Party. Only employees of the Parties can be appointed to serve on the R&D Committee. The R&D Committee shall meet periodically (but in any event no less than quarterly) during the performance of the Feasibility Program and Development Plan. In the event that, during the term of a Feasibility Program, the members of the R&D Committee cannot agree on an issue within the scope of its authority within thirty (30) days of its initial consideration, the matter shall be referred by either co-chairpersons in writing to one (1) expert, the identity of whom shall be mutually agreed upon, for a reasoned determination in writing. In the event that, during the term of the Development Plan, the members of the R&D Committee cannot agree on a recommendation to be made to Teva, then the members appointed by Teva shall have a casting vote in respect of such recommendation.
Research and Development Committee. 11 3.3 Management of the Clinical Program..................... 11 3.4
Research and Development Committee. 3.1. The Parties will establish and maintain a Research and Development Committee (the “R&D Committee”) throughout the R&D Program. The R&D Committee shall have the authority to approve, update and monitor the R&D Program and the R&D Budget and any material deviation therefrom, and generally monitor performance thereunder. The R&D Committee shall make decisions on issues that arise in respect of the R&D Program and its performance and shall establish and periodically review all draft protocols and draft reports, draft expert reports, draft summaries and final versions of same, and the commercial objectives and activities set forth as part of the R&D Program. The R&D Committee shall be comprised of four members, having one vote each, of which two shall be appointed by each Party, including one co-chairperson appointed by each party. The R&D Committee shall meet (either in person by video conference or by telephone) periodically (but in any event no less than quarterly) during the course of the R&D Program.
Research and Development Committee. BIOGEN shall use commercially reasonable efforts to develop OP-1 PROTEIN for use in the FIELD (the "PRODUCT DEVELOPMENT PROGRAM"). BIOGEN shall use commercially reasonable efforts to concurrently develop OP-1 PROTEIN for the treatment of acute and chronic renal failure. A Research and Development Committee (the "R&D Committee") shall be established by the parties to oversee and monitor the PRODUCT DEVELOPMENT PROGRAM, including research, process development, product development, clinical, regulatory and production of preclinical and clinical supplies of PRODUCTS. The day-to-day activities of the R&D COLLABORATION, described hereinafter in Section 8, will be overseen and monitored by the R&D Committee as described herein.
Research and Development Committee. Each party shall designate two representatives ("Designated Representatives") to serve on a Research and Development Committee ("Committee") to determine and monitor the priorities, goals, budgets, resource allocations and milestones for the ongoing clinical development of the Products.
